The Authors Reply Thank you for your letter regarding our case report (1). In end-stage kidney disease patients, the prolonged half-life of ceftriaxone can reportedly increase the concentration of the drug in plasma. In general, the proteinunbound free fraction of drugs can freely penetrate the blood-brain/blood-cerebrospinal fluid (CSF) barrier. As for ceftriaxone, about 90% to 95% of the drug is protein-bound, so it rarely penetrates the blood-CSF barrier (2); in addition, the elimination of ceftriaxone in CSF is considerably slower than that in serum (3). A previous report suggested that the accumulation of cephalosporins in the central nervous system might lead to the development of neurological manifestations (4).
